Vifor Pharma Stock

Vifor Pharma Debt 2024

Vifor Pharma Debt

-406.6 CHF

Ticker

VIFN.SW

ISIN

CH0364749348

WKN

A2DRZ4

In 2024, Vifor Pharma's total debt was -406.6 CHF, a 0% change from the 0 CHF total debt recorded in the previous year.

Vifor Pharma Aktienanalyse

What does Vifor Pharma do?

Vifor Pharma AG is a leading pharmaceutical company based in St. Gallen, Switzerland. The company has a long history and over 100 years of experience in the manufacturing of pharmaceutical products. It was founded in 1872 as Etablissements Gallois and has undergone various mergers and acquisitions. Today, it is part of the global Galenica Group and has branches in over 30 countries. Vifor Pharma AG focuses on the development and production of medications for the treatment of iron deficiency and kidney diseases. It diversifies its business across different market segments and geographic regions. The company's well-known products include iron preparations sold under different brands such as Ferinject, Injectafer, and Venofer, used for the treatment of iron deficiency anemia in both intravenous and tablet forms. another important business area for Vifor Pharma AG is nephrology, with a wide range of kidney and dialysis products available, including treatments for hyperphosphatemia and anemia in dialysis patients. To strengthen its innovation, the company has invested in partnerships, such as an exclusive license for the distribution of Vadadustat, an oral medication for the treatment of anemia in chronic kidney disease. Vifor Pharma AG has also invested in the digitalization and data-driven technologies, acquiring a stake in the Austrian company medisign GmbH in 2020 to expand its expertise in digital health and telemedicine. In terms of sustainability, the company aims to be carbon-neutral by 2025 and has implemented measures to reduce its CO2 footprint. With its long history, diverse portfolio of products and services, and investments in innovation and sustainability, Vifor Pharma AG is well-positioned for future success. Vifor Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Vifor Pharma's Debt Structure

Vifor Pharma's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Vifor Pharma's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Vifor Pharma’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Vifor Pharma’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Vifor Pharma stock

What is the debt of Vifor Pharma this year?

Vifor Pharma has a debt level of -406.6 CHF this year.

What was the debt of Vifor Pharma compared to the previous year?

The debt of Vifor Pharma has increased by 0% compared to the previous year dropped.

What are the consequences of high debt for investors in Vifor Pharma?

High debt can pose a risk for investors of Vifor Pharma, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Vifor Pharma?

Low debt means that Vifor Pharma has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Vifor Pharma affect the company?

An increase in debt of Vifor Pharma can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Vifor Pharma affect the company?

A reduction in debt of Vifor Pharma can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Vifor Pharma?

Some factors that can influence the debt of Vifor Pharma include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Vifor Pharma so important for investors?

The debts of Vifor Pharma are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Vifor Pharma take to change the debt?

To change the debt, Vifor Pharma can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Vifor Pharma pay?

Over the past 12 months, Vifor Pharma paid a dividend of 2 CHF . This corresponds to a dividend yield of about 1.2 %. For the coming 12 months, Vifor Pharma is expected to pay a dividend of 6.28 CHF.

What is the dividend yield of Vifor Pharma?

The current dividend yield of Vifor Pharma is 1.2 %.

When does Vifor Pharma pay dividends?

Vifor Pharma pays a quarterly dividend. This is distributed in the months of June, June, June, May.

How secure is the dividend of Vifor Pharma?

Vifor Pharma paid dividends every year for the past 24 years.

What is the dividend of Vifor Pharma?

For the upcoming 12 months, dividends amounting to 6.28 CHF are expected. This corresponds to a dividend yield of 3.78 %.

In which sector is Vifor Pharma located?

Vifor Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vifor Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vifor Pharma from 5/3/2022 amounting to 2 CHF, you needed to have the stock in your portfolio before the ex-date on 4/29/2022.

When did Vifor Pharma pay the last dividend?

The last dividend was paid out on 5/3/2022.

What was the dividend of Vifor Pharma in the year 2023?

In the year 2023, Vifor Pharma distributed 2 CHF as dividends.

In which currency does Vifor Pharma pay out the dividend?

The dividends of Vifor Pharma are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Vifor Pharma

Our stock analysis for Vifor Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vifor Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.